Dr. Reddy's Laboratories Ltd reported its financial results for the fourth quarter of fiscal year 2025, with revenue rising 19.9% year-on-year to Rs 8,528 crore and a 21.1% increase in profit after tax (PAT) to Rs 1,587 crore. However, its EBITDA saw a 12.1% decline quarter-on-quarter to Rs 1,998 crore. Following these results, Bank of America maintained a 'buy' rating on the stock, although Emkay downgraded the price target to Rs 1,050 citing margin concerns. Meanwhile, Motilal Oswal upgraded Aurobindo Pharma to a 'buy' rating with a target price of Rs 1,360, highlighting attractive valuations after a 25% drop from its peak. Navin Fluorine International Ltd posted a 16.4% year-on-year revenue increase to Rs 701 crore and a 62.4% rise in EBITDA to Rs 179 crore, supported by major orders, capacity expansion, and the China-plus-one strategy. Aarti Pharmalabs Ltd reported an 11.5% revenue increase to Rs 564 crore and a 35.4% rise in PAT to Rs 88 crore for the quarter. UPL Ltd showed strong growth with net profit surging to Rs 896 crore from Rs 40 crore year-on-year, revenue increasing 10.6% to Rs 15,573 crore, and EBITDA rising 67% to Rs 3,235 crore, with margins improving to 20.8%. PVR Inox reported a net loss of Rs 125 crore, slightly lower than the previous year's Rs 130 crore loss, with revenue down 0.5% to Rs 1,250 crore and a 1.5% increase in EBITDA to Rs 283.3 crore, improving margins to 22.7%.